Aldurazyme Articles
BioMarin to acquire LEAD Therapeutics for $18 million plus $68 million more on milestone
5 February 2010
FDA finds trash particles in Genzyme’s drugs, leading firm to advise health care providers
16 November 2009
Third-quarter 2009 profit sinks at Genzyme, on production woes
22 October 2009
FDA issues warning letter on Genzyme facility
9 March 2009
Genzyme's 2008 profit down on costs
23 February 2009
Genzyme's 3rd-qtr 2008 profit down 25%
3 November 2008
Genzyme's 2nd qtr profit hit by license cost
4 August 2008
BioMarin's 1st-qtr beats analyst expectations
12 May 2008
Genzyme's 1st-qtr revenues jump 25%
5 May 2008
Genzyme's 4th-qtr 2007 revenue jumps 21%
25 February 2008
Strong third quarter for Genzyme: GAAP net income reaches $159M on the back of good sales
5 November 2007
BioMarin's 2nd-qtr 2007 loss widens to $3.9M
20 August 2007
Genzyme's 2nd-qtr net income jumps 4%
6 August 2007
Medicines Australia welcomes govt boost
14 May 2007
Genzyme's 1st-qtr net income soars 57%
7 May 2007
Genzyme guidance upped on good 2nd qtr
25 July 2005
Genzyme's 1st-qtr revenues up 28%
25 April 2005
BioMarin's 3rd-qtr net loss widens
22 November 2004
BioMarin sees 2nd-qtr loss rocket on Ascent acquisition
16 August 2004
New Chemical Entities in 2003
19 January 2004
TKT and Genzyme sign deal for I2S
27 October 2003
EU clears Genzyme, BioMarin drug for MPS
23 June 2003
US orphan drug costs "up 40% per year"
9 June 2003
FDA clears Genzyme, BioMarin drug for MPS
12 May 2003
4th-qtr charges hit Genzyme General
17 March 2003
Aldurazyme backed by CPMP
3 March 2003
Aldurazyme approvable, says US FDA
3 February 2003
Stock Commentary - week to Jan 20 - New York
27 January 2003
BioMarin's loss grows
19 August 2002
BioMarin gains US patent on Aldurazyme
5 August 2002
BioMarin, Genzyme on track with MPS-1 drug
1 July 2002
Stock Commentary - New York
1 July 2002
BioMarin, Genzyme on track with MPS-1 drug
1 July 2002
"Rolling" BLA filed in USA for Aldurazyme
22 April 2002
BioMarin/Genzyme file Aldurazyme in Europe
15 April 2002
BioMarin completes $96.6 million public offering
13 December 2001
BioMarin to sell 6 million shares
12 November 2001
BioMarin, Genzyme to file MPS-1 therapy
5 November 2001
Losses deepen at BioMarin
26 October 2001
BioMarin Pharma gets $45 million boost
18 May 2001
MPS-I patients benefit from Aldurazyme
17 May 2001
BioMarin Aldurazyme Ph II enrollment
2 March 2001
BioMarin gets boost as Acqua Wellington puts in $50 million
2 February 2001
Merck to seek Vioxx OK for rheumatoid arthritis
24 November 2000
Second BioMarin enzyme enters trials
16 October 2000
Stock Commentary New York
25 November 1999
BioMarin and Genzyme to conduct additional Ph III Aldurazyme trial
24 November 1999
Showing 1-56 of 56 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
